PE20160858A1 - Analogos carba-nucleosidicos para tratamiento antiviral - Google Patents

Analogos carba-nucleosidicos para tratamiento antiviral

Info

Publication number
PE20160858A1
PE20160858A1 PE2016000758A PE2016000758A PE20160858A1 PE 20160858 A1 PE20160858 A1 PE 20160858A1 PE 2016000758 A PE2016000758 A PE 2016000758A PE 2016000758 A PE2016000758 A PE 2016000758A PE 20160858 A1 PE20160858 A1 PE 20160858A1
Authority
PE
Peru
Prior art keywords
carba
treatment
nucleosidic
antiviral treatment
methyltetrahydrofuran
Prior art date
Application number
PE2016000758A
Other languages
English (en)
Inventor
Thomas Butler
Jie Xu
Choung U Kim
Aesop Cho
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42333309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160858(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20160858A1 publication Critical patent/PE20160858A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invencion se refiere a compuestos analogos carba-nucleosidicos de formula I donde R1, R2, R3, R4, R5 o R6 son H, CN, NO2, entre otros; R7 es H, entre otros; R8, R9 y R10 son H, halogeno, entre otros; X2 es O, S, entre otros. Son compuestos preferidos: (2R,3R,4R,5R)-2-(4-aminotieno[3,4-d]pirimidin-7-yl)-5-(hidroximetil)-3-metilltetrahidrofuran-3,4-diol; 2-amino-7-[(2R,3R,4R,5R)-3,4-dihidroxi-5-(hidroximetil)-3-metiltetrahidrofuran-2-il]tieno[3,4-d]pirimidin-4(3H)-ona, entre otros. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos compuestos inhiben ARN polimerasa dependiente de ARN de VHC (RdRp) de virus de la familia Flaviviridae, siendo utiles en el tratamiento de infecciones virales por Flaviviridae
PE2016000758A 2009-02-10 2010-02-09 Analogos carba-nucleosidicos para tratamiento antiviral PE20160858A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15124809P 2009-02-10 2009-02-10

Publications (1)

Publication Number Publication Date
PE20160858A1 true PE20160858A1 (es) 2016-09-03

Family

ID=42333309

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2016000564A PE20161067A1 (es) 2009-02-10 2010-02-09 Analogos carba-nucleosidicos para tratamiento antiviral
PE2016000758A PE20160858A1 (es) 2009-02-10 2010-02-09 Analogos carba-nucleosidicos para tratamiento antiviral
PE2011001464A PE20120257A1 (es) 2009-02-10 2010-02-09 Analogos carba-nucleosidicos para tratamiento antiviral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016000564A PE20161067A1 (es) 2009-02-10 2010-02-09 Analogos carba-nucleosidicos para tratamiento antiviral

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001464A PE20120257A1 (es) 2009-02-10 2010-02-09 Analogos carba-nucleosidicos para tratamiento antiviral

Country Status (27)

Country Link
US (1) US8012942B2 (es)
EP (2) EP2719701B1 (es)
JP (2) JP5746638B2 (es)
KR (2) KR101724759B1 (es)
CN (1) CN102348713B (es)
AP (1) AP2922A (es)
AU (3) AU2010213873B2 (es)
BR (1) BRPI1013643A2 (es)
CA (1) CA2751277C (es)
CL (1) CL2011001906A1 (es)
CO (1) CO6420354A2 (es)
DK (1) DK2396340T3 (es)
EA (1) EA025085B1 (es)
ES (2) ES2628842T3 (es)
HK (1) HK1163108A1 (es)
HR (1) HRP20140219T1 (es)
IL (1) IL214396A (es)
MX (2) MX2011008409A (es)
NZ (1) NZ594370A (es)
PE (3) PE20161067A1 (es)
PL (1) PL2396340T3 (es)
PT (2) PT2719701T (es)
SG (1) SG173186A1 (es)
SI (1) SI2396340T1 (es)
SM (1) SMT201400056B (es)
UA (2) UA112140C2 (es)
WO (1) WO2010093608A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
KR101681559B1 (ko) 2008-04-23 2016-12-01 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 1'-치환된 카바-뉴클레오사이드 유사체
WO2011035250A1 (en) 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
EP2596004B1 (en) 2010-07-19 2014-09-10 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
MX2013000744A (es) 2010-07-22 2013-03-07 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae.
JP2013538230A (ja) * 2010-09-20 2013-10-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013084165A1 (en) * 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
IN2014MN01547A (es) 2012-02-10 2015-05-08 Lupin Ltd
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
EP2852603B1 (en) 2012-05-22 2021-05-12 Idenix Pharmaceuticals LLC D-amino acid compounds for liver disease
UY34824A (es) 2012-05-25 2013-11-29 Janssen R & D Ireland Nucleósidos de espirooxetano de uracilo
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CN105814068B (zh) * 2014-02-27 2017-08-04 四川海思科制药有限公司 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
CA2978085C (en) 2015-03-06 2023-01-17 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
EP3288957A4 (en) * 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER
US10251904B2 (en) 2015-09-16 2019-04-09 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
CN106083962B (zh) * 2016-06-08 2018-12-18 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
CN110248951B (zh) 2017-02-01 2022-10-28 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
KR102318320B1 (ko) 2017-03-14 2021-10-27 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
US20230365608A1 (en) * 2019-02-01 2023-11-16 Janssen Biopharma, Inc. Antiviral nucleosides and derivatives thereof
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN115298181A (zh) 2020-03-12 2022-11-04 吉利德科学公司 制备1’-氰基核苷的方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
KR20230018473A (ko) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 렘데시비르 치료 방법
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
EP4204421A2 (en) 2020-08-27 2023-07-05 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
WO2001032153A2 (en) 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
JP2003523978A (ja) 2000-02-18 2003-08-12 シャイアー・バイオケム・インコーポレイテッド ヌクレオシドアナログを用いるｆｌａｖｉｖｉｒｕｓ感染の処置もしくは予防するための方法
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CA2426187C (en) 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
JP2005536440A (ja) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
EP3109244B1 (en) 2004-09-14 2019-03-06 Gilead Pharmasset LLC Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US8133870B2 (en) * 2004-10-29 2012-03-13 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
CA2672613A1 (en) 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8071568B2 (en) 2007-01-05 2011-12-06 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
CN101611046A (zh) 2007-01-12 2009-12-23 拜奥克里斯特制药公司 抗病毒的核苷类似物
AU2008251555B2 (en) 2007-05-10 2012-08-30 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs

Also Published As

Publication number Publication date
DK2396340T3 (en) 2014-03-10
EP2396340A1 (en) 2011-12-21
BRPI1013643A2 (pt) 2016-04-19
CL2011001906A1 (es) 2012-03-30
NZ594370A (en) 2014-01-31
CN102348713A (zh) 2012-02-08
EP2396340B1 (en) 2013-12-18
SG173186A1 (en) 2011-09-29
EP2719701B1 (en) 2017-04-05
PE20120257A1 (es) 2012-03-29
US8012942B2 (en) 2011-09-06
ES2628842T3 (es) 2017-08-04
AU2017202413A1 (en) 2017-05-04
WO2010093608A1 (en) 2010-08-19
AU2017202413B2 (en) 2018-09-13
KR101724759B1 (ko) 2017-04-07
UA110093C2 (uk) 2015-11-25
KR101834707B1 (ko) 2018-03-05
JP5951690B2 (ja) 2016-07-13
AP2011005818A0 (en) 2011-08-31
AP2922A (en) 2014-05-31
US20100203015A1 (en) 2010-08-12
CA2751277A1 (en) 2010-08-19
ES2453078T3 (es) 2014-04-03
MX345562B (es) 2017-02-03
EA025085B1 (ru) 2016-11-30
AU2010213873A1 (en) 2011-09-01
SI2396340T1 (sl) 2014-04-30
PT2396340E (pt) 2014-03-26
IL214396A (en) 2014-07-31
PL2396340T3 (pl) 2014-05-30
PT2719701T (pt) 2017-06-29
HK1163108A1 (en) 2012-09-07
KR20170039759A (ko) 2017-04-11
UA112140C2 (uk) 2016-07-25
AU2010213873B2 (en) 2015-07-09
AU2015238785A1 (en) 2015-10-29
AU2015238785B2 (en) 2017-02-16
HRP20140219T1 (hr) 2014-04-11
EA201190110A1 (ru) 2012-02-28
PE20161067A1 (es) 2016-10-23
JP2014185183A (ja) 2014-10-02
JP5746638B2 (ja) 2015-07-08
EP2719701A1 (en) 2014-04-16
CO6420354A2 (es) 2012-04-16
CA2751277C (en) 2018-10-30
KR20110116046A (ko) 2011-10-24
MX2011008409A (es) 2011-10-21
JP2012517444A (ja) 2012-08-02
CN102348713B (zh) 2015-12-02
IL214396A0 (en) 2011-09-27
SMT201400056B (it) 2014-07-07

Similar Documents

Publication Publication Date Title
PE20161067A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
PE20091424A1 (es) Nucleosidos 2',4'-sustituidos como agentes antivirales
AR075584A1 (es) COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CO6321235A2 (es) Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral
EA201500304A1 (ru) Аналоги 2'-хлоро нуклеозидов для инфекции вгс
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA
PE20060677A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones que los contienen
ECSP12012282A (es) Fosforamidatos de nucleósido
HRP20150725T1 (hr) Kondenzirani imidazolilimidazoli kao antivirusni spojevi
PE20160658A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
PE20091727A1 (es) Agentes terapeuticos antivirales
EA201170915A1 (ru) Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
GT200200117A (es) Derivados de nucleosidos
PA8588501A1 (es) Derivados antivirales de nucleósidos
AR082068A2 (es) Analogos de nucleosidos fluorados modificados
EA200701850A1 (ru) Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
ES2322602T3 (es) Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
EA201390141A1 (ru) 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
CO6382185A2 (es) Compuestos nucleosidos antivirales
SV2005001919A (es) Compuestos nucleosidos para el tratamiento de infecciones virales
HN2008000497A (es) Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica
UY28110A1 (es) Derivados de nucleosido antivirales
CY1115086T1 (el) Αναλογα καρβα-νουκλεοζιτων για αντιϊικη αγωγη

Legal Events

Date Code Title Description
FD Application declared void or lapsed